Literature DB >> 23082789

Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes.

Emi Kimoto1, Kenta Yoshida, Larissa M Balogh, Yi-An Bi, Kazuya Maeda, Ayman El-Kattan, Yuichi Sugiyama, Yurong Lai.   

Abstract

Since the substrate specificities of OATP1B1, 1B3, and 2B1 are broad and overlapping, the contribution of each isoform to the overall hepatic uptake is of concern when assessing transporter-mediated drug-drug interactions (DDIs) or genetic polymorphism impact in the clinic. Herein, we quantitatively measured OATP proteins in cryopreserved hepatocytes, sandwich-cultured human hepatocytes (SCHH), and the liver, and examined the relationship with functional uptake of OATP substrates in an effort to identify the OATP isoform(s) contributing to the hepatic uptake of pitavastatin. The modulation of OATP expression in SCHH was found to be lot-dependent. However, OATP protein measurements averaged from 5 lots of SCHH were comparable to that of suspended hepatocytes. All three OATP transporters in suspended hepatocytes and SCHH were significantly lower than those in the liver. In SCHH, the uptake of CCK-8 and pravastatin was found to be associated with the expression of OATP1B3 and OATP1B1, respectively. In suspended hepatocytes, OATP1B1 appeared to show a positive trend with respect to the uptake of pitavastatin, which suggests a selective contribution of OATP1B1 to pitavastatin transport and thus an OATP quantitative protein expression-activity relationship. While the passive diffusion of rosuvastatin in SCHH was consistent across hepatocyte lots, the passive diffusion of pitavastatin varied over a broad range (>4-fold) in suspended hepatocytes and was inversely correlated with transporter-mediated uptake, presumably due to cell membrane alterations imparted by cryopreservation. Collectively, SCHH maintains OATP protein expression and membrane integrity and, if feasible when considering research goals, would be considered a superior tool for the characterization of in vitro transport parameters without the complication of membrane leakage.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23082789     DOI: 10.1021/mp300379q

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  24 in total

1.  Herb-drug interactions: challenges and opportunities for improved predictions.

Authors:  Scott J Brantley; Aneesh A Argikar; Yvonne S Lin; Swati Nagar; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2013-12-11       Impact factor: 3.922

2.  Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex.

Authors:  Bhagwat Prasad; Raymond Evers; Anshul Gupta; Cornelis E C A Hop; Laurent Salphati; Suneet Shukla; Suresh V Ambudkar; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2013-10-11       Impact factor: 3.922

3.  Response to the comment on the article "physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions".

Authors:  Manthena V S Varma; Yurong Lai; Bo Feng; John Litchfield; Theunis C Goosen; Arthur Bergman
Journal:  Pharm Res       Date:  2013-03-06       Impact factor: 4.200

Review 4.  Quantitative targeted proteomics for membrane transporter proteins: method and application.

Authors:  Xi Qiu; Hui Zhang; Yurong Lai
Journal:  AAPS J       Date:  2014-05-15       Impact factor: 4.009

5.  Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.

Authors:  Thomayant Prueksaritanont; Xiaoyan Chu; Raymond Evers; Stephanie O Klopfer; Luzelena Caro; Prajakti A Kothare; Cynthia Dempsey; Scott Rasmussen; Robert Houle; Grace Chan; Xiaoxin Cai; Robert Valesky; Iain P Fraser; S Aubrey Stoch
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

Review 6.  Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.

Authors:  Kyunghee Yang; Cen Guo; Jeffrey L Woodhead; Robert L St Claire; Paul B Watkins; Scott Q Siler; Brett A Howell; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2016-02       Impact factor: 3.534

Review 7.  Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.

Authors:  Rui Li; Hugh A Barton; Manthena V Varma
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

8.  Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.

Authors:  Michael Gertz; Nikolaos Tsamandouras; Carolina Säll; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2014-03-13       Impact factor: 4.200

9.  Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.

Authors:  Manthena V S Varma; Yurong Lai; Emi Kimoto; Theunis C Goosen; Ayman F El-Kattan; Vikas Kumar
Journal:  Pharm Res       Date:  2013-01-10       Impact factor: 4.200

10.  Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide.

Authors:  Manthena V S Varma; Renato J Scialis; Jian Lin; Yi-An Bi; Charles J Rotter; Theunis C Goosen; Xin Yang
Journal:  AAPS J       Date:  2014-05-17       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.